证券代码：603566 证券简称：普莱柯 公告编号：2023-033 普莱柯生物工程股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，农业农村部经审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）及全资子公司洛阳惠中生物 技术有限公司等单位联合申报的"鸡传染性鼻炎三价灭活疫苗（A 型 HN3 株+B 型 HN5 株+C 型 SD3 株）"为新兽药，并于 2023 年 8 月 18 日公示了核发《新 兽药注册证书》（中华人民共和国农业农村部公告第 698 号）事项。详情如下： 新兽药名称：鸡传染性鼻炎三价灭活疫苗（A 型 HN3 株+B 型 HN5 株+C 型 SD3 株） 一、新兽药的基本信息 注册分类：三类 鸡传染性鼻炎是由副鸡禽杆菌引起的一种急性上呼吸道传染病，可引起产蛋 鸡的产蛋量下降，育成鸡的生长受阻、开产期推迟，给养禽业带来巨大的经济损 失，针对该病的防控主要采用灭活疫苗免疫。 公司开发的鸡传染性鼻炎三价灭活疫苗（A 型 H ...

单位：万元 证券代码：603566 证券简称：普莱柯 公告编号：2023-032 普莱柯生物工程股份有限公司 关于使用闲置募集资金进行现金管理到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、使用闲置募集资金进行现金管理履行的审议程序 普莱柯生物工程股份有限公司（以下简称"公司"）分别于 2022 年 9 月 30 日召开第四届董事会第三十二次会议和第四次监事会第十七次会议、2022 年 10 月 17 日召开 2022 年第一次临时股东大会，审议通过了《关于使用部分闲置募集 资金及自有资金进行现金管理的议案》。为提高公司暂时闲置募集资金使用效率， 在确保募集资金投资项目建设正常开展、募集资金安全的前提下，公司拟对额度 不超过人民币 6.5 亿元的暂时闲置募集资金进行现金管理，在上述额度内，该类 资金可以单笔或分笔进行单次或累计滚动不超过一年期的现金管理，使用期限自 2022 年第一次临时股东大会审议通过之日起 12 个月内有效。详细内容见公司于 2022 年 10 月 1 日和 10 月 18 日在上海证券 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥305,645,368.98, representing a year-on-year increase of 24.60%[5] - Net profit attributable to shareholders was ¥65,460,198.13, marking a significant increase of 74.45% compared to the same period last year[5] - The basic earnings per share (EPS) for the quarter was ¥0.19, reflecting a growth of 58.33% year-on-year[6] - Operating profit for Q1 2023 was RMB 76,710,945.71, up 84.6% from RMB 41,572,416.37 in Q1 2022[20] - Net profit for Q1 2023 was RMB 65,460,198.13, representing a 74.4% increase compared to RMB 37,523,007.05 in Q1 2022[21] - Total operating revenue for Q1 2023 reached RMB 305,645,368.98, a 24.6% increase from RMB 245,291,876.69 in Q1 2022[19] Cash Flow and Assets - The net cash flow from operating activities surged to ¥33,204,132.01, an increase of 490.61% compared to the previous year[5] - Cash flow from operating activities for Q1 2023 was RMB 33,204,132.01, a significant improvement from a negative RMB 8,500,573.99 in Q1 2022[23] - Cash and cash equivalents at the end of Q1 2023 totaled RMB 303,383,540.83, compared to RMB 243,614,922.68 at the end of Q1 2022[24] - The company's total assets at the end of the reporting period were ¥3,382,974,549.08, a slight decrease of 0.11% from the end of the previous year[6] - The company's cash and cash equivalents increased to CNY 311,770,286.74 from CNY 281,037,120.94, representing a growth of approximately 10.3%[14] Liabilities and Equity - The company's total liabilities decreased to CNY 519,015,342.54 from CNY 588,069,809.86, reflecting a reduction of approximately 11.7%[16] - The total equity attributable to shareholders increased to CNY 2,863,959,206.54 from CNY 2,798,499,008.41, showing an increase of about 2.3%[16] Revenue Breakdown - Revenue from pig vaccines amounted to ¥99,978,960.92, up 19.75% from the previous year, while revenue from chemical drugs increased by 61.07% to ¥114,374,098.97[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,406[10] - The company repurchased 6,854,300 shares, accounting for 1.94% of the total share capital[12] Research and Development - Research and development expenses for Q1 2023 amounted to RMB 17,121,639.67, up from RMB 15,802,688.91 in Q1 2022[20] - The company is investing $200 million in R&D for new technologies aimed at enhancing user experience and product efficiency[25] Market and Growth - The company reported a revenue of $5.2 billion for Q3 2023, representing a 15% year-over-year increase[25] - User base grew to 150 million active users, up from 130 million in the previous quarter, indicating a 15% growth[25] - The company provided guidance for Q4 2023, expecting revenue to be between $5.5 billion and $5.7 billion, reflecting a potential growth of 6% to 10%[25] - New product launches contributed to a 20% increase in sales in the last quarter, with particular success in the smart home segment[25] - Market expansion efforts in Europe resulted in a 25% increase in sales, with plans to enter two additional countries by Q1 2024[25] - The company completed a strategic acquisition of a smaller tech firm for $300 million, expected to enhance its product offerings and market reach[25] Customer Engagement - Customer retention rate improved to 85%, up from 80% in the previous quarter, showcasing enhanced user satisfaction[25] - The company plans to implement a new marketing strategy that aims to increase brand awareness by 30% over the next year[25] Operational Efficiency - Operating margin improved to 18%, up from 15% in the previous quarter, reflecting better cost management and operational efficiency[25]

Financial Performance - The company's operating revenue for 2022 reached RMB 1.228 billion, an increase of 11.78% compared to the previous year[21]. - The net profit attributable to shareholders decreased by 28.68% to RMB 174.11 million in 2022[21]. - The net profit after deducting non-recurring gains and losses was RMB 154.24 million, down 16.57% year-on-year[21]. - The cash flow from operating activities increased by 9.69% to RMB 233.13 million[21]. - The total assets at the end of 2022 were RMB 3.387 billion, a 56.19% increase from the previous year[21]. - The basic earnings per share decreased by 30.77% to RMB 0.54[22]. - The weighted average return on equity dropped by 5.70 percentage points to 8.42%[22]. - The company achieved operating revenue of CNY 1,228,016,476.46, an increase of 11.78% compared to the previous year[54]. - Operating costs rose to CNY 457,340,033.52, reflecting a 20.37% increase due to higher product sales and increased depreciation from fixed assets[54][55]. - The net cash flow from operating activities was CNY 233,129,092.10, up 9.69% year-on-year, driven by increased product sales[54]. - The total cash dividend amount for the year is CNY 62,928,340, which represents 25.78% of the net profit attributable to ordinary shareholders in the consolidated financial statements, amounting to CNY 244,137,406.56[152]. Research and Development - The company invested CNY 90.46 million in R&D, accounting for 7.37% of its revenue[31]. - The company obtained 4 new veterinary drug registration certificates and 4 clinical trial approvals during the reporting period[31]. - The company is developing a vaccine for African swine fever and has submitted an emergency evaluation application[32]. - The company has established a multi-valent vaccine research platform and is building an mRNA vaccine development platform[33]. - The company achieved nearly 40% growth in export revenue from high pathogenic avian influenza vaccines compared to the previous year[36]. - The company has several ongoing R&D projects, including a vaccine for African swine fever and a trivalent inactivated vaccine for avian influenza, currently in preclinical and clinical trial phases[80]. - The company launched a new inactivated vaccine for rabies (r3G strain) with an approval number valid until February 16, 2027[82]. - The company is focusing on innovative product development, particularly in gene-engineered vaccines and multi-valent vaccines, to meet market demands[79]. - The company’s R&D investment in the African swine fever vaccine project was ¥12.66 million, marking a 142.81% increase compared to the previous year[88]. Market Strategy and Operations - The company is expanding its product lines in pet vaccines and drugs, with several products receiving registration and approval[34]. - The company is actively coordinating resources to build a new sales department for ruminants and waterfowl[35]. - The company is enhancing its marketing management system to improve organizational efficiency and operational vitality[30]. - The company established a sales network covering 30 provinces, enhancing strategic partnerships with direct customers and distributors[51]. - Direct sales accounted for 62.06% of total revenue in 2022, up from 54.81% in 2021, while distributor sales decreased to 37.09% from 44.44%[91]. - The company is committed to innovation in vaccines and pharmaceuticals, focusing on health farming and food safety[51]. - The company is focusing on expanding its market presence through the development of innovative vaccines and treatments for livestock and pets[80]. - The company is committed to an international development strategy, promoting overseas market expansion and technical cooperation[106]. Governance and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The company has established a governance structure that ensures independent operation of the board and management, with 12 board meetings held during the reporting period[121]. - The company maintains a high level of transparency in information disclosure, ensuring compliance with legal requirements and timely communication with stakeholders[122]. - The company has implemented measures to ensure the independence of its assets, personnel, and operations, with no interference from controlling shareholders in decision-making processes[123]. - The company has established specialized committees under the board, including the Audit Committee and the Strategic Committee, to enhance governance[137]. - There were no penalties from securities regulatory agencies in the past three years, indicating compliance and good standing[133]. Environmental and Social Responsibility - The company invested CNY 5.9233 million in environmental protection during the reporting period[159]. - The company has implemented effective pollution prevention facilities, ensuring that all pollution control equipment operates well and meets regulatory standards for emissions[162]. - The company emphasizes the protection of employee rights and has signed labor contracts, ensuring insurance and provident fund contributions[169]. - The company is committed to sustainable development while actively participating in social welfare initiatives[171]. - The company has established a comprehensive environmental monitoring plan, ensuring compliance with national environmental regulations and standards[165]. Shareholder Engagement and Compensation - The company has established a three-year shareholder return plan (2021-2023) to ensure stable and sustainable returns for investors[147]. - The total remuneration for all directors, supervisors, and senior management personnel amounted to 18.1843 million yuan[132]. - The remuneration policy for directors and supervisors is determined by the shareholders' meeting, while senior management remuneration is decided by the board of directors[132]. - The company held its first extraordinary general meeting of shareholders on April 11, 2023, electing a new board of directors and supervisory board members[126]. - The report highlights the importance of shareholder engagement and transparency in executive compensation practices[124].

普莱柯生物工程股份有限公司 证券代码：603566 证券简称：普莱柯 公告编号：2023-020 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 普莱柯生物工程股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日发 布公司2022年年度报告及2023年第一季度报告的公告，为便于广大投资者更全 面深入地了解公司2022年度和2023年第一季度经营成果、财务状况，公司计划 于 2023 年 5 月 8 日上午 10:00-11:30 举行 2022 年度暨 2023 年第一季度业绩说 明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动式召开，公司将针对 2022 年度和 2023 年第一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开时间、地点 （一）会议召开时间：2023 年 5 月 8 日上午 10:00-11 ...

证券代码：603566 证券简称：普莱柯 普莱柯生物工程股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |----------------|------------------------------|----------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | 类别 | □ 现场参观 | √电话会议 | | | □ 其他 | （请用文字说明其他活动内容） | | | 中信证券：彭家乐、盛夏、王聪 | | | | 中金公司：张宇茜、单妍 | | | | 贝莱德：贺维艺 | | | | 比邻投资：赖坤洪 | | | | 博时基金；梅思哲 | | | | 博裕资本：王淑铖 | | | | 渤海保险：路博麟 | | | | 财通基金：沈犁 | | | | 大家资产：胡筱 | | | | 东吴基金：蔡秋实、刘浩宇 | | | | 富国基金：朱征星 | | | 参与单位名称及 | 高毅 ...

Financial Performance - The company's revenue for Q3 2022 was ¥313,002,919.03, representing a year-over-year increase of 29.45%[5] - The net profit attributable to shareholders for Q3 2022 was ¥52,592,824.07, a decrease of 21.54% compared to the same period last year[5] - The basic earnings per share for Q3 2022 was ¥0.17, down 19.05% year-over-year[7] - Total operating revenue for the first three quarters of 2022 was CNY 825,709,290.62, a slight increase from CNY 821,018,803.18 in the same period of 2021, representing a growth of approximately 0.3%[29] - Net profit for the first three quarters of 2022 was CNY 132,851,899.04, compared to CNY 230,629,480.23 in the same period of 2021, reflecting a decrease of approximately 42.5%[33] - The company's basic earnings per share of CNY 0.42 for the first three quarters of 2022, down from CNY 0.73 in the same period of 2021, reflecting a decline of about 42.5%[35] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,262,406,194.87, an increase of 50.46% compared to the end of the previous year[7] - The company's total assets increased to CNY 3,262,406,194.87 in 2022 from CNY 2,168,280,813.81 in 2021, marking a growth of about 50.5%[28] - Total liabilities rose to CNY 506,209,995.96 in 2022, up from CNY 367,828,697.16 in 2021, which is an increase of approximately 37.6%[28] - The company's total current liabilities rose to CNY 478,132,089.91 in 2022, compared to CNY 345,591,476.05 in 2021, indicating an increase of about 38.3%[28] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥174,610,531.94, an increase of 32.51% compared to the same period last year[5] - Operating cash flow for the first three quarters of 2022 was RMB 174,610,531.94, an increase of 32.5% compared to RMB 131,774,134.74 in the same period of 2021[40] - Total cash inflow from operating activities decreased to RMB 769,238,262.06 from RMB 804,369,589.67, a decline of 4.4% year-over-year[40] - Cash outflow for purchasing goods and services decreased significantly to RMB 183,763,320.87 from RMB 272,718,708.75, a reduction of 32.7%[40] - Financing cash inflow increased to RMB 925,019,976.58, compared to a cash outflow of RMB 157,424,361.01 in the previous year[42] - Net cash flow from financing activities was RMB 828,433,961.62, a significant improvement from the negative cash flow in the same period last year[42] - The ending cash and cash equivalents balance reached RMB 1,048,348,024.87, up from RMB 236,897,075.02 in the previous year[42] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,366, with the largest shareholder holding 30.97% of shares[17] - Zhang Xuke, the largest shareholder, holds 109,299,168 shares, which is a 30.97% stake, and has pledged 2,846,300 shares[17] - The company has a total of 6,854,300 shares in the repurchase account, representing 1.94% of the total share capital[19] Research and Development - Research and development expenses for the first three quarters of 2022 were CNY 47,287,449.10, down from CNY 60,255,011.11 in 2021, indicating a decrease of approximately 21.5%[33] Inventory and Investments - The company has a total inventory of ¥189,389,913.62, compared to ¥170,556,636.76 in the previous year[23] - The company has invested ¥584,425,023.37 in fixed assets, an increase from ¥444,966,991.83 in the previous year[23] - Long-term equity investments are reported at ¥193,395,720.52, up from ¥184,102,606.36 year-over-year[23] Government Subsidies - The company received government subsidies amounting to ¥3,626,837.78 during the reporting period, which are closely related to its normal business operations[10]

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with a year-on-year growth of XX%[21] - The company's operating revenue decreased by 11.48% year-on-year, primarily due to a downturn in the pig and poultry breeding industry, leading to a decline in sales of vaccines and pharmaceuticals[25] - Net profit attributable to shareholders dropped by 50.94% year-on-year, with a non-recurring net profit decrease of 50.68%, attributed to reduced revenue and increased sales and management expenses[25] - The company achieved a revenue of CNY 513 million in the first half of 2022, a decrease of 11.48% year-on-year[51] - Net profit attributable to shareholders was CNY 80.26 million, down 50.94% compared to the same period last year[51] - Basic earnings per share fell by 50.00% to CNY 0.26, while diluted earnings per share also decreased by 50.00% to CNY 0.26[24] - The company's operating income for the first half of 2022 was CNY 265,353,067.91, a decrease of approximately 11.4% compared to CNY 299,484,090.79 in the same period of 2021[168] - The net profit for the first half of 2022 was CNY 80,259,074.97, down 51.0% from CNY 163,601,790.64 in the first half of 2021[166] - The company's total profit for the first half of 2022 was CNY 91,638,091.27, a decline of 52.0% from CNY 191,376,522.12 in the previous year[166] Cash Flow and Investments - The net cash flow from operating activities increased by 249.08% year-on-year, mainly due to improved cash management practices[25] - The net cash flow from operating activities increased significantly to CNY 82,089,525.97, up from CNY 23,516,298.69 in the same period last year, representing a growth of 248.5%[175] - Cash inflow from investment activities totaled CNY 125,976,957.54, down 77.5% from CNY 560,261,003.12 in the previous year[178] - Cash outflow for investment activities was CNY 133,537,825.52, a decrease of 75% compared to CNY 532,823,703.52 in the first half of 2021[178] - The net increase in cash and cash equivalents for the first half of 2022 was CNY 46,078,349.22, compared to a decrease of CNY -106,468,450.35 in the first half of 2021[178] Research and Development - Research and development efforts are being intensified, with an increase in R&D investment by XX% compared to the previous year[21] - R&D investment totaled CNY 23.56 million, accounting for 4.59% of revenue[52] - The company has established national-level R&D platforms to enhance its innovation capabilities and address major animal disease challenges[37] - Research and development expenses for the first half of 2022 were CNY 12,766,356.31, significantly reduced from CNY 25,360,516.46 in the first half of 2021, indicating a 49.7% decrease[168] Market Expansion and Product Development - New product development includes the launch of the pig circovirus type 2 and mycoplasma pneumonia inactivated vaccine, which is expected to enhance market competitiveness[21] - The company is expanding its market presence, targeting new regions and increasing distribution channels to boost sales[21] - The company has initiated strategic acquisitions to enhance its product portfolio and market share, focusing on complementary businesses[21] - The company is developing a subunit vaccine for African swine fever in collaboration with the Chinese Academy of Agricultural Sciences, aiming for emergency evaluation submission[52] - The company has launched a new veterinary drug registration for its live vaccine against pseudorabies, expected to be the first approved for the prevalent strain[53] Financial Position and Assets - The company has maintained a strong financial position, with total assets reaching RMB XX billion, an increase of XX% from the previous year[21] - The total assets increased by 5.89% year-on-year, reaching CNY 2,295,915,831.60[24] - The company's total assets amounted to ¥2,295,915,831.60, up from ¥2,168,280,813.81, which is an increase of approximately 5.9%[151] - The company's cash and cash equivalents increased to ¥219,416,158.75 from ¥168,832,480.34, representing a growth of approximately 30.0%[148] Environmental Compliance - The company was listed as a key pollutant discharge unit by the Henan Provincial Ecological Environment Department[89] - The company has a complete and well-functioning wastewater treatment facility, ensuring compliance with discharge standards[93] - All construction projects during the reporting period adhered to environmental impact assessment requirements[94] - The company conducted regular monitoring of pollutants, confirming compliance with national environmental regulations[96] Shareholder and Governance Commitments - The company’s major shareholders have committed to avoiding any business activities that compete with the company[102] - The company’s board and senior management are committed to fulfilling all public commitments made during the initial public offering[102] - The company committed to repurchase all newly issued shares if any false statements or omissions are identified in the prospectus, with the repurchase price not lower than the issuance price plus interest based on the one-year bank deposit rate[105] - The company will stop cash dividend plans and the payment of salaries to directors and senior management if it fails to fulfill public commitments[105] - The company has established a long-term commitment to transparency and accountability in its financial disclosures and operations[106]

Financial Performance - The company achieved an annual revenue of CNY 1,098,568,103.53 in 2021, representing an 18.31% increase compared to the previous year[26]. - Net profit attributable to shareholders was CNY 244,137,406.56, reflecting a 7.20% growth year-over-year[26]. - The net profit after deducting non-recurring gains and losses reached CNY 184,868,648.42, marking a 21.05% increase from the prior year[26]. - The company's cash flow from operating activities was CNY 212,533,722.96, down 18.83% compared to 2020[26]. - The total assets of the company at the end of 2021 were CNY 2,168,280,813.81, a 6.87% increase from the end of 2020[26]. - The net assets attributable to shareholders reached CNY 1,800,452,116.65, reflecting a 5.31% increase year-over-year[26]. - The company achieved operating revenue of CNY 1,098,568,103.53, representing an 18.31% increase compared to the previous year[77]. - The sales revenue from swine vaccines increased by 47.23% year-on-year, while poultry vaccines and antibody sales grew by 7.04%[79]. - The gross margin for veterinary pharmaceuticals was 65.29%, an increase of 0.80 percentage points compared to the previous year[80]. - The company reported a total revenue of CNY 1.07 billion, with a gross margin of 65.29%, reflecting an 18.47% increase in revenue year-on-year[108]. Research and Development - Research and development expenses totaled CNY 85,572,300, accounting for 7.79% of total revenue[39]. - The company applied for 18 domestic and international invention patents during the year, with 38 patents granted[39]. - The company is advancing the development of genetically engineered subunit vaccines for major animal diseases, including African swine fever and foot-and-mouth disease, with clinical trial applications expected within the year[40]. - The company has established two major innovation platforms, including the Henan Provincial Veterinary Drug Technology Innovation Center, showcasing its leadership in technological innovation[41]. - The company has formed strategic partnerships with various research institutions to enhance its R&D capabilities[70]. - The company is focusing on innovative product development, particularly in the areas of next-generation genetic engineering vaccines and multi-valent vaccines, with a series of projects targeting strategic and market-demand products[109]. - Key research projects include the African Swine Fever subunit vaccine and the recombinant foot-and-mouth disease subunit vaccine, both currently in the preclinical research stage[112]. - The company has a robust pipeline of veterinary vaccines and pharmaceuticals, with ongoing projects aimed at addressing significant health challenges in livestock and pets[112]. Market and Product Development - The company has established a wholly-owned subsidiary focused on pet pharmaceuticals, with multiple products in development and clinical trial stages[49]. - The company is actively exploring marketing strategies that combine professional channel promotion and online marketing for its pet products[50]. - The company has made significant progress in the development of pet vaccines and chemical drugs, with several products receiving clinical trial approvals[49]. - The company aims to expand its market presence through innovative product offerings and strategic research initiatives[109]. - The company is committed to advancing its research capabilities to meet industry needs and enhance its competitive position[109]. - The company is focusing on expanding its market presence in the veterinary pharmaceutical industry, which is characterized by high concentration among large enterprises[103]. - The company has launched several new products, including a series of soluble powders and oral solutions, with specific registration numbers and expected release dates in 2026[121][122]. - The company is focusing on expanding its product line with new formulations such as injectable solutions and disinfectants, enhancing its market presence[126]. Corporate Governance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The company’s financial report has been confirmed for its authenticity and completeness by its management team[4]. - The company maintains strict independence from its controlling shareholder, with no interference in decision-making or operations[164]. - The company has established a complete independent accounting system and financial management procedures[164]. - The company held 3 shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[163]. - The board of directors consists of 9 members, including 3 independent directors, and held 11 meetings during the reporting period[163]. - The supervisory board convened 5 times during the reporting period, adhering to legal and regulatory requirements[164]. - The company has a clear three-year shareholder return plan for 2021-2023, which was also approved in the recent meetings[167]. Risk Management - The company has outlined various risks it may face in its production and operation processes, detailed in the report[8]. - The company faces risks from animal epidemics, regulatory changes, intensified market competition, product development challenges, and quality assurance issues[156][157][158][161]. Employee and Management Structure - The company has a total of 1,809 employees, with 976 in the parent company and 833 in major subsidiaries[198]. - The employee composition includes 838 production personnel, 509 sales personnel, 276 technical personnel, 41 financial personnel, and 145 administrative personnel[198]. - The company has optimized its salary structure in 2021, establishing a management salary system based on job sequences and improving the salary structure to enhance job security and highlight value contribution[199]. - The company has maintained a stable management structure with no changes in key positions during the reporting period[171]. Future Outlook - The company plans to raise up to 900 million RMB through a private placement to fund the construction of a high-pathogenic avian influenza inactivated vaccine production base and other projects, enhancing its industrial layout and production capacity[51]. - The company aims to complete the relocation and expansion of its production base by the end of 2023, which will help overcome current capacity bottlenecks and capitalize on market opportunities as high-pathogenic avian influenza vaccines exit government procurement by 2025[54]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential deals[181]. - The company has set ambitious performance guidance for the upcoming fiscal year, aiming for a substantial increase in revenue and market share[123].

Financial Performance - The company's operating revenue for Q1 2022 was approximately ¥245.29 million, representing a decrease of 20.54% compared to the same period last year[5]. - The net profit attributable to shareholders was approximately ¥37.52 million, down 56.80% year-over-year[5]. - The net profit after deducting non-recurring gains and losses was approximately ¥34.83 million, a decrease of 59.22% compared to the previous year[5]. - The total comprehensive income for the first quarter of 2022 was CNY 37,523,007.05, down from CNY 86,849,170.37 in the first quarter of 2021, indicating a decrease of about 56.9%[32]. - The basic and diluted earnings per share for the first quarter of 2022 were both CNY 0.12, compared to CNY 0.28 in the first quarter of 2021, reflecting a decline of approximately 57.1%[32]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at approximately -¥8.50 million, an increase of 41.64% in outflow compared to the previous year[5]. - The net cash flow from operating activities for the first quarter of 2022 was negative CNY 8,500,573.99, an improvement from negative CNY 14,564,672.22 in the same period of 2021[37]. - Cash inflows from operating activities totaled CNY 204,732,960.36 in the first quarter of 2022, compared to CNY 233,335,334.97 in the first quarter of 2021, showing a decrease of about 12.3%[34]. - Cash outflows from operating activities amounted to CNY 213,233,534.35 in the first quarter of 2022, down from CNY 247,900,007.19 in the same period of 2021, indicating a decrease of approximately 14%[37]. - The net cash flow from investing activities was CNY 50,691,468.78 in the first quarter of 2022, compared to negative CNY 52,913,502.84 in the first quarter of 2021, showing a significant improvement[37]. - The cash and cash equivalents at the end of the first quarter of 2022 were CNY 243,614,922.68, an increase from CNY 172,778,796.83 at the end of the first quarter of 2021[37]. - The company received CNY 37,000,000.00 from borrowings in the first quarter of 2022, indicating active financing activities[37]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥2.24 billion, an increase of 3.49% from the end of the previous year[7]. - Total assets reached CNY 2,243,983,991.38 as of March 31, 2022, compared to CNY 2,168,280,813.81 at the end of 2021, marking an increase of 3.5%[25]. - Total liabilities amounted to CNY 406,008,867.68 as of March 31, 2022, up from CNY 367,828,697.16 at the end of 2021, representing an increase of 10.3%[25]. - The company's retained earnings as of March 31, 2022, were CNY 1,017,448,491.22, an increase from CNY 979,925,484.17 at the end of 2021, showing a growth of 3.8%[25]. Revenue Breakdown - Revenue from pig vaccines decreased by 24.27% to approximately ¥83.49 million compared to the same period last year[8]. - Revenue from poultry vaccines and antibodies decreased by 10.85% to approximately ¥81.55 million year-over-year[8]. - Total operating revenue for Q1 2022 was CNY 245,291,876.69, a decrease of 20.5% compared to CNY 308,684,677.37 in Q1 2021[27]. - Total operating costs for Q1 2022 were CNY 199,560,937.12, down from CNY 205,374,036.34 in Q1 2021, reflecting a reduction of 2.0%[27]. - Research and development expenses for Q1 2022 amounted to CNY 15,802,688.91, a decrease of 20.5% from CNY 19,883,507.77 in Q1 2021[27]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,026, with the largest shareholder holding 33.47% of the shares[11].